The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13:497-510; PMID:23760024; http://dx.doi.org/10.1038/nrc3486
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705; PMID:17320507; http://dx.doi.org/10.1016/j.cell.2007.02.005
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13:673-91; PMID:25131830; http://dx.doi.org/10.1038/nrd4360
   PubMed Web of Science ®Google Scholar
• Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011; 3:145-55; PMID:21743813; http://dx.doi.org/10.2217/epi.11.12
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-99; PMID:12120280; http://dx.doi.org/10.1038/nrd772
   PubMed Web of Science ®Google Scholar
• Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008; 57:647-54; PMID:18046553; http://dx.doi.org/10.1007/s00262-007-0402-4
   PubMed Web of Science ®Google Scholar
• Khan AN, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med 2007; 5:64-75; PMID:18070359; http://dx.doi.org/10.1186/1479-5876-5-64
   PubMed Web of Science ®Google Scholar
• Magner WJ, Tomasi TB. Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol Immunol 2005; 42:1033-42; PMID:15829293; http://dx.doi.org/10.1016/j.molimm.2004.09.030
   PubMed Web of Science ®Google Scholar
• Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004; 53:748-54; PMID:14997346; http://dx.doi.org/10.1007/s00262-004-0513-0
   PubMed Web of Science ®Google Scholar
• West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 2013; 73:7265-76; PMID:24158093; http://dx.doi.org/10.1158/0008-5472.CAN-13-0890
   PubMed Web of Science ®Google Scholar
• Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 2012; 91:701-9; PMID:22028329; http://dx.doi.org/10.1189/jlb.0311119
   PubMed Web of Science ®Google Scholar
• Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307; PMID:17922010; http://dx.doi.org/10.1038/nm1652
   PubMed Web of Science ®Google Scholar
• Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117:1205-17; PMID:20956800; http://dx.doi.org/10.1182/blood-2010-05-284711
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124:30-9; PMID:24382387; http://dx.doi.org/10.1172/JCI69738
   PubMed Web of Science ®Google Scholar
• Zhang Z, Convertini P, Shen M, Xu X, Lemoine F, de la Grange P, Andres DA, Stamm S. Valproic acid causes proteasomal degradation of DICER and influences miRNA expression. PLoS One 2013; 8:e82895; PMID:24358235; http://dx.doi.org/10.1371/journal.pone.0082895
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15:509-24; PMID:25027649; http://dx.doi.org/10.1038/nrm3838
   PubMed Web of Science ®Google Scholar
• Kurzynska-Kokorniak A, Koralewska N, Pokornowska M, Urbanowicz A, Tworak A, Mickiewicz A, Figlerowicz M. The many faces of Dicer: the complexity of the mechanisms regulating Dicer gene expression and enzyme activities. Nucleic Acids Res 2015; 43:4365-80; PMID:25883138; http://dx.doi.org/10.1093/nar/gkv328
   PubMed Web of Science ®Google Scholar
• Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009; 284:17897-901; PMID:19342379; http://dx.doi.org/10.1074/jbc.R900012200
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. Dicer is essential for mouse development. Nat Genet 2003; 35:215-7; PMID:14528307; http://dx.doi.org/10.1038/ng1253
   PubMed Web of Science ®Google Scholar
• Devasthanam AS, Tomasi TB. Dicer in immune cell development and function. Immunol Invest 2014; 43:182-95; PMID:24303839; http://dx.doi.org/10.3109/08820139.2013.863557
   PubMed Web of Science ®Google Scholar
• Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39:673-7; PMID:17401365; http://dx.doi.org/10.1038/ng2003
   PubMed Web of Science ®Google Scholar
• Pellegrino L, Jacob J, Roca-Alonso L, Krell J, Castellano L, Frampton AE. Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers. Expert Rev Anticancer Ther 2013; 13:21-7; PMID:23259424; http://dx.doi.org/10.1586/era.12.150
   PubMed Web of Science ®Google Scholar
• Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res 2015; 21:4767-73; PMID:26362997; http://dx.doi.org/10.1158/1078-0432.CCR-15-0530
   PubMed Web of Science ®Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009; 280:233-41; PMID:19344997; http://dx.doi.org/10.1016/j.canlet.2009.02.019
   PubMed Web of Science ®Google Scholar
• Lu J, Yang C, Chen M, Ye DY, Lonser RR, Brady RO, Zhuang Z. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A 2011; 108:21200-5; PMID:22160715; http://dx.doi.org/10.1073/pnas.1119181109
   PubMed Web of Science ®Google Scholar
• Kim SH, Kang HJ, Na H, Lee MO. Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein. Breast Cancer Res 2010; 12:R22; PMID:20388208; http://dx.doi.org/10.1186/bcr2562
   PubMed Web of Science ®Google Scholar
• Scognamiglio A, Nebbioso A, Manzo F, Valente S, Mai A, Altucci L. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008; 1783:2030-8; PMID:18691615; http://dx.doi.org/10.1016/j.bbamcr.2008.07.007
   PubMed Web of Science ®Google Scholar
• Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26:2019-28; PMID:16507982; http://dx.doi.org/10.1128/MCB.26.6.2019-2028.2006
   PubMed Web of Science ®Google Scholar
• Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004; 10:8094-104; PMID:15585645; http://dx.doi.org/10.1158/1078-0432.CCR-04-1023
   PubMed Web of Science ®Google Scholar
• Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22:3411-20; PMID:12840003; http://dx.doi.org/10.1093/emboj/cdg315
   PubMed Web of Science ®Google Scholar
• Magner WJ, Weinstock-Guttman B, Rho M, Hojnacki D, Ghazi R, Ramanathan M, Tomasi TB. Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. J Neuroimmunol 2016; 292:68-78; PMID:26943961; http://dx.doi.org/10.1016/j.jneuroim.2016.01.009
   PubMed Web of Science ®Google Scholar
• Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015; 20:3898-941; PMID:25738536; http://dx.doi.org/10.3390/molecules20033898
   PubMed Web of Science ®Google Scholar
• Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 2014; 25:140-9; PMID:24185382; http://dx.doi.org/10.1097/CAD.0000000000000040
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15:3958-69; PMID:19509172; http://dx.doi.org/10.1158/1078-0432.CCR-08-2785
   PubMed Web of Science ®Google Scholar
• Wiesen JL, Tomasi TB. Dicer is regulated by cellular stresses and interferons. Mol Immunol 2009; 46:1222-8; PMID:19118902; http://dx.doi.org/10.1016/j.molimm.2008.11.012
   PubMed Web of Science ®Google Scholar
• Singh S, Bevan SC, Patil K, Newton DC, Marsden PA. Extensive variation in the 5′-UTR of Dicer mRNAs influences translational efficiency. Biochem Biophys Res Commun 2005; 335:643-50; PMID:16095561; http://dx.doi.org/10.1016/j.bbrc.2005.07.138
   PubMed Web of Science ®Google Scholar
• Irvin-Wilson CV, Chaudhuri G. Alternative initiation and splicing in dicer gene expression in human breast cells. Breast Cancer Res 2005; 7:R563-9; PMID:15987463; http://dx.doi.org/10.1186/bcr1043
   PubMedGoogle Scholar
• Giles KE, Ghirlando R, Felsenfeld G. Maintenance of a constitutive heterochromatin domain in vertebrates by a Dicer-dependent mechanism. Nat Cell Biol 2010; 12:94-9; sup pp 1-6
   PubMed Web of Science ®Google Scholar
• Fukagawa T, Nogami M, Yoshikawa M, Ikeno M, Okazaki T, Takami Y, Nakayama T, Oshimura M. Dicer is essential for formation of the heterochromatin structure in vertebrate cells. Nat Cell Biol 2004; 6:784-91; PMID:15247924; http://dx.doi.org/10.1038/ncb1155
   PubMed Web of Science ®Google Scholar
• van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun 2014; 5:5203; PMID:25351418; http://dx.doi.org/10.1038/ncomms6203
   PubMed Web of Science ®Google Scholar
• Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, Imai K, Shinomura Y, Tokino T, Baylin SB. A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res 2008; 68:2570-5; PMID:18413723; http://dx.doi.org/10.1158/0008-5472.CAN-07-6405
   PubMed Web of Science ®Google Scholar
• Ho JJ, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M, Petruzziello-Pellegrini TN, Tsui AK, He JZ, Dhamko H, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 2012; 287:29003-20; PMID:22745131; http://dx.doi.org/10.1074/jbc.M112.373365
   PubMed Web of Science ®Google Scholar
• Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P, Voinnet O. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol 2012; 14:1314-21; PMID:23143396; http://dx.doi.org/10.1038/ncb2611
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Shi Y, Kage-Nakadai E, Mitani S, Xue D. Caspase-dependent conversion of Dicer ribonuclease into a death-promoting deoxyribonuclease. Science 2010; 328:327-34; PMID:20223951; http://dx.doi.org/10.1126/science.1182374
   PubMed Web of Science ®Google Scholar
• Matskevich AA, Moelling K. Stimuli-dependent cleavage of Dicer during apoptosis. Biochem J 2008; 412:527-34; PMID:18289125; http://dx.doi.org/10.1042/BJ20071461
   PubMed Web of Science ®Google Scholar
• Guan Y, Yao H, Wang J, Sun K, Cao L, Wang Y. NF-kappaB-DICER-miRs Axis Regulates TNF-alpha Expression in Responses to Endotoxin Stress. Int J Biol Sci 2015; 11:1257-68; PMID:26435691; http://dx.doi.org/10.7150/ijbs.12611
   PubMed Web of Science ®Google Scholar
• Jafarnejad SM, Ardekani GS, Ghaffari M, Martinka M, Li G. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. Oncogene 2013; 32:2131-9; PMID:22689055; http://dx.doi.org/10.1038/onc.2012.239
   PubMed Web of Science ®Google Scholar
• Levy C, Khaled M, Robinson KC, Veguilla RA, Chen PH, Yokoyama S, Makino E, Lu J, Larue L, Beermann F, et al. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 2010; 141:994-1005; PMID:20550935; http://dx.doi.org/10.1016/j.cell.2010.05.004
   PubMed Web of Science ®Google Scholar
• Hsieh TH, Hsu CY, Tsai CF, Long CY, Wu CH, Wu DC, Lee JN, Chang WC, Tsai EM. HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells. Mol Ther 2015; 23:656-66; PMID:25531695; http://dx.doi.org/10.1038/mt.2014.247
   PubMed Web of Science ®Google Scholar
• Cho JH, Dimri M, Dimri GP. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015; 290:10555-67; PMID:25737447; http://dx.doi.org/10.1074/jbc.M114.624361
   PubMed Web of Science ®Google Scholar
• Wang JH, Shih KS, Wu YW, Wang AW, Yang CR. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1beta signaling in osteoarthritis fibroblast-like synoviocytes. Osteoarthritis Cartilage 2013; 21:1987-96; PMID:24107356; http://dx.doi.org/10.1016/j.joca.2013.09.008
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66:1277-81; PMID:16452179; http://dx.doi.org/10.1158/0008-5472.CAN-05-3632
   PubMed Web of Science ®Google Scholar
• Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000; 165:7017-24; PMID:11120829; http://dx.doi.org/10.4049/jimmunol.165.12.7017
   PubMed Web of Science ®Google Scholar